Strategic partnerships Dune Medical has sold assets to Dilon Diagnostics and pursued collaboration in real-time cancer detection technologies via MarginProbe. This suggests potential for channel partnerships or OEM opportunities to leverage existing distribution networks and clinical adoption momentum.

Clinical expansion With a history of in-man trials and RF spectroscopy platform expansions aimed at smart biopsies, there is opportunity to target hospitals and biopsy centers seeking real-time margin assessment capabilities and enhanced surgical precision.

Clinical leadership Key hires in R&D, CFO, and Commercial leadership indicate a company scaling focus and potential for sales cycles requiring strategic value propositions, multi-stakeholder engagement, and education for procurement committees.

Financial readiness Revenue scale and a substantial funding runway (revenue roughly in the low millions with $50M in funding) imply capacity for capital equipment deployments, bundled service agreements, and phased adoption in larger health systems.

Tech ecosystem Dune’s tech stack and emphasis on RF spectroscopy, MarginProbe applications, and real-time cancer detection align with radiology and surgical departments seeking advanced diagnostic tools, enabling cross-selling with related imaging and analytics solutions.